Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing an antibody therapy for Alzheimer's by targeting toxic AβOs.
ABOS | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 1210-1220 WASHINGTON STREET, 2465 NEWTON
- Website:
- https://acumenpharm.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer's disease. The company's therapeutic approach is based on decades of research into toxic soluble amyloid-beta oligomers (AβOs), which are considered a primary driver of neurodegeneration. Its lead candidate, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target these toxic AβOs. Acumen aims to deliver a disease-modifying treatment for patients with early-stage Alzheimer's, with the goal of providing therapeutic benefits alongside an improved safety profile.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Acumen Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Acumen Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Acumen Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
